Latest news

EM Imaging at EIE16

adminEM Imaging at EIE16
read more

Edinburgh Molecular Imaging and Mauna Kea Technologies Announce Clinical Molecular Imaging Collaboration

 

 

 

Edinburgh and Paris, April 6th, 2016 – Edinburgh Molecular Imaging Ltd (EM Imaging) and Mauna Kea Technologies (Euronext: MKEA, OTCQX: MKEAY) today announced a clinical research collaboration to study the potential of combining EM Imaging’s in vivo optical imaging agents and Mauna Kea’s confocal laser endomicroscopy platform to diagnose cancer.  The combination of novel molecular imaging agents and advanced visualisation such as endomicroscopy is a promising avenue for advancing personalised cancer diagnosis.

 

In a first study, EM Imaging will supply EMI-137, a safe and well-tolerated clinical grade investigational molecular optical imaging agent to two investigational sites to perform clinical efficacy studies in pancreatic and lung cancers. The Edinburgh Royal Infirmary will evaluate suspected lung cancer patients while Groningen Medical Centre will study EMI-137 in early stage pancreatic cancer. Both centres will image EMI-137 in real time at the cellular level using endomicroscopy with Cellvizio.

 

Intravenous administration of EMI-137 leads to its selective accumulation in c-Met–expressing tumours, which can then be detected optically via fluorescent markers that are attached to the molecular imaging agent. c-Met is a receptor tyrosine kinase, whose over-expression is known to be associated with tumour growth and correlates with a poor clinical prognosis in many cancer types.

 

“We have been at the forefront of image-guided surgery with novel molecular markers and advanced imaging modalities for several years. With Cellvizio and EMI-137, we will now enable for the first time highly specific real-time imaging at the cellular level in solid tumors” said Prof Go Van Dam, Professor of Surgical Oncology, and Dr Wouter Nagengast  from the Optical Molecular Imaging Group (OMIG) at the University Medical Center Groningen (UMCG). “This combination of molecular markers, targeted macroscopic image-guided surgery/endoscopy and endomicroscopy represents a significant clinical milestone that we are about to embark upon.”

 

“Lung Cancer is the biggest cancer killer in the world and any methodologies that could allow us to improve diagnosis, treatment monitoring and surgical resection are urgently required” said Dr Kev Dhaliwal, Senior Lecturer in Pulmonary Molecular Imaging at the University of Edinburgh and Consultant Pulmonologist at the Royal Infirmary of Edinburgh. “, We will evaluate the potential impact of Cellivizo and EMI-137 in our patients working alongside surgeons and pulmonologists at the University of Edinburgh”.

 

In a second project, it is planned that EM Imaging will provide EMI-200, a neutrophil targeting optical molecular imaging agent developed for topical administration in the lung. The presence of neutrophils in the lung is correlated to an inflammatory response and as such is clinically useful in the acute care setting to improve diagnosis of critically ill patients. Studies will be performed under an investigator-sponsored eIND (Emergency Investigational New Drug) at Cleveland Clinic in acute care patients. In this study, the Cellvizio platform will also be used to image neutrophil activity in real-time at the cellular level.

 

“Early detection and verification of disease at the point of care continues to be a major challenge to patient care and management” said Ian Wilson, CEO of EM Imaging. “This collaboration potentially addresses these major unmet medical needs by combining targeted molecular agents with the most advanced imaging technology available to improve disease detection and guide intervention. We look forward to pioneering this approach with Mauna Kea and our clinical partners.”

 

“Combining our unique endomicroscopy platform with highly-specific molecular markers from EM Imaging is another key milestone in our development strategy to bring in vivo examination to a level never reached by existing standards. We are delighted to partner with EM Imaging and  leading clinical institutions such as the UMCG, Cleveland Clinic and Edinburgh  with the common goal to revolutionize the way cancer patients are diagnosed.” said Sacha Loiseau, Ph.D., CEO and founder of Mauna Kea Technologies, ”We continue to deliver on our ambitious roadmap and look forward to the first in-human clinical results of this cutting-edge endeavour.”

 

About Edinburgh Molecular Imaging (www.emimaging.com)

EM Imaging is a diagnostic company, with a comprehensive R&D portfolio, focused on the development and commercialisation of optical molecular imaging agents. The EM Imaging team is made up of industry and academic experts in the field of imaging, chemistry, clinical development, regulatory affairs and commercialisation of in vivo diagnostic imaging products.

 

 

About Mauna Kea Technologies

Mauna Kea Technologies is a global medical device company focused on eliminating diagnostic and treatment uncertainties thanks to direct visualization at the cellular level. The Company’s flagship product, Cellvizio, has received clearance to sell for a wide range of applications in more than 40 countries, including the United States, Europe, Japan, China, Canada, Brazil and Mexico. For more information on Mauna Kea Technologies, visit www.maunakeatech.com.

adminEdinburgh Molecular Imaging and Mauna Kea Technologies Announce Clinical Molecular Imaging Collaboration
read more

Edinburgh Molecular imaging Ltd awarded Innovate UK grant to qualify the role of EMI-137 in colorectal cancer lesion detection

Edinburgh Molecular imaging Ltd (EM Imaging) announced today that the company has received a SBRI Stratified Medicine Connecting the UK Infrastructure Phase I grant from the UK’s innovation agency, Innovate UK. The SBRI grant aims to accelerate and increase the development and adoption of innovative diagnostic tools in order to offer better targeted treatment to patients within the UK healthcare system. It also aims to demonstrate the benefits of companies working within the UK ‘enabling infrastructure’, which is made up of specialist organisations that can help companies understand healthcare needs, and design, evaluate and deliver their products and services into the NHS.

 

EM Imaging is partnering with the National Institute for Health Research Colorectal Therapies Healthcare Technology Co-operative (NIHR Colorectal Therapies HTC) and the NIHR Diagnostic Evidence Co-operative Leeds (NIHR DEC Leeds), both based at the Leeds Teaching Hospitals NHS Trust to qualify the potential role of the novel optical imaging agent EMI-137 for the improved detection of colorectal (CRC) lesion during colonoscopy.

 

Phase I of the SBRI project will provide an initial demonstration of the clinical and economic utility of EMI-137, thereby providing key inputs for the design of a potential follow-on Phase II SBRI and future clinical studies to be undertaken by EM imaging.

 

Ian Wilson, CEO of EMI, commented: “EM Imaging are extremely grateful to Innovate UK for their award to formalise the health economic value of EMI-137. The detection of flat, smaller non-polypoid lesion is problematic, which cannot be detected by conventional imaging. EMI-137 potentially addresses this major unmet medical need, by combining targeted molecular probes and advanced imaging technology to improve polyp detection. The whole EM Imaging team is extremely motivated to complete this product’s development and get it into the hands of physicians in order to benefit patients.”

 

Professor David Jayne, Professor of Surgery at the University of Leeds and Clinical Director of the NIHR Colorectal Therapies HTC in Leeds said: “We are delighted to be working closely with EM Imaging on an Innovate UK-funded project to evaluate an exciting new technique for detecting early bowel tumours. EM Imaging’s novel fluorescent molecular probe can help doctors detect more bowel tumours during colonoscopy. This will allow the tumours to be removed before they get to an advanced stage and therefore improve the outlook for the many patients who suffer from this condition.”

 

About EMI-137

GE-137, a water-soluble probe consisting of a 26–amino acid cyclic peptide that binds the human tyrosine kinase c-Met conjugated to a fluorescent cyanine dye. Intravenous administration of GE-137 leads to its accumulation specifically in c-Met–expressing tumours, and it is safe and well tolerated in humans. Fluorescence colonoscopy in patients receiving intravenous GE-137 enabled visualization of all neoplastic polyps that were visible with white light, as well as an additional previously missed polyps that were not visible with white light. The first-in-human pilot study, published in Nature Medicine shows that molecular imaging using an intravenous fluorescent agent specific for c-Met is feasible and safe, and that it may enable the detection of polyps missed by other techniques.

 

About Edinburgh Molecular Imaging

EM imaging is a diagnostics company, with a comprehensive R&D portfolio, focused on the development and commercialisation of Optical Imaging agents. The EM Imaging team is made up of academic and industry experts in the field of imaging, chemistry, clinical development, regulatory affairs and commercialisation of in vivo diagnostic imaging products.

 

About NIHR’s Colorectal Therapies Healthcare Technology Co-operative and Diagnostic Evidence Co-operative Leeds

The National Institute for Health Research (NIHR) is funded by the Department of Health to improve the health and wealth of the nation through research. The NIHR is the research arm of the NHS. Since its establishment in April 2006, the NIHR has transformed research in the NHS. It has increased the volume of applied health research for the benefit of patients and the public, driven faster translation of basic science discoveries into tangible benefits for patients and the economy, and developed and supported the people who conduct and contribute to applied health research. The NIHR plays a key role in the Government’s strategy for economic growth, attracting investment by the life-sciences industries through its world-class infrastructure for health research. Together, the NIHR people, programmes, centres of excellence and systems represent the most integrated health research system in the world. For further information, visit the NIHR website (www.nihr.ac.uk).

The National Institute for Health Research has funded four Diagnostic Evidence Co-operatives (DECs) to help generate information on the clinical and cost-effectiveness of in vitro diagnostic devices which are important in helping to improve the way diseases are diagnosed. This will help patients access the most appropriate treatments more quickly and help the NHS make the best use of its resources.

The Academic Unit of Health Economics (AUHE) at the University of Leeds specialises in evaluations of diagnostic tests and works collaboratively with the NIHR DEC Leeds.

 

The NIHR Colorectal Therapies HTC is a national network that provides expertise in biomedical science, clinical application and commercialisation to advance the care of patients with colorectal diseases. Through a structured and collaborative approach the HTC defines clinical areas in need of innovation and develops novel solutions that are progressed to clinical practice.

 
Further information:

 

Edinburgh Molecular Imaging

 

info@emimaging.com

www.emimaging.com

adminEdinburgh Molecular imaging Ltd awarded Innovate UK grant to qualify the role of EMI-137 in colorectal cancer lesion detection
read more

EM Imaging finalist at Pitch@Palace

EM Imaging has been selected  as one of the 14 teams that will Pitch on Monday 7th March, 2016 at St. James’s Palace. In addition, there will be a Peoples Choice vote and we would appreciate if our followers could vote for us at the following link.

ow.ly/YI6dN

 

 

 

adminEM Imaging finalist at Pitch@Palace
read more

Edinburgh Molecular Imaging to Pitch@Palace

Edinburgh Molecular Imaging have been announced as finalists at the Duke of York’s ‘Pitch at the Palace’ competition, which is designed to help entrepreneurs develop their business ideas. The team  will pitch to HRH Duke of York and 300 business people at St James’s Palace on 7 March.

adminEdinburgh Molecular Imaging to Pitch@Palace
read more

EM Imaging obtains global licence for optical agent that detects cancer early

Edinburgh, United Kingdom, 16 th September, 2015 – Edinburgh Molecular Imaging Ltd. (EM Imaging) has signed an exclusive global license for a novel optical imaging agent that could improve the detection of early-stage colorectal (bowel) cancer.

EM Imaging, a company which develops and commercialises novel optical imaging agents, recently signed the licensing agreement with GE Healthcare Ltd. and Dyax Inc. EM Imaging will now complete the development of this unique imaging agent “EMI-137” that can help doctors identify colorectal (bowel) cancer early.

In a recent scientific study, reported in the prestigious scientific journal Nature Medicine, the EMI-137 agent allowed doctors to see more early-stage colorectal cancer (CRC) and precancerous tumours, which can then easily be removed via colonoscopy. However, screening with a colonoscope, which is currently the most common method, can miss up to 25% of precancerous growths, especially smaller, flat lesions.

Dr James Hardwick, the lead investigator on the study published in Nature Medicine said:

“Of the 47 precancerous polyps detected in this study, 12 were missed using a standard colonoscope. This underlines how unreliable this method can be, and we therefore welcome life-saving new technology like EMI-137. This agent has the potential to make polyps light up like light bulbs – allowing clinicians to detect and remove more polyps, prevent more cancers and save more lives.”

Evidence that colorectal cancer can be prevented by the removal of pre-cancerous lesions and polyps (abnormal growth of tissue) is strong. The EMI-137 agent can help doctors more easily identify these suspicious lesions, take a sample (biopsy) or remove the lesion completely. Colorectal cancer is the second most common cause of cancer in women and the third most common in men, and is a major cause of death.

The Phase I/IIa study (Nature Medicine Link), in 35 subjects (20 healthy volunteers and 15 patients with high risk of CRC) shows that optical molecular imaging using the fluorescent agent specific for c-Met is feasible and safe.

Fluorescence colonoscopy in patients receiving intravenous EMI-137 enabled the visualisation of all neoplastic polyps that were visible with white light, and additionally, detected previously missed polyps that were not visible with white light alone. This enables the detection of polyps missed by other techniques.

EMI-137 is a water-soluble compound consisting of a 26–amino acid cyclic peptide, conjugated to a fluorescent cyanine dye, that binds to human tyrosine kinase c-Met, a receptor frequently overexpressed during cancer growth. EMI-137 has the potential on intravenous administration to image a wide range of cancers including, breast cancer, oesophageal cancer, ovarian cancer, thyroid cancer, bile duct carcinoma and lung cancer, due to its specific targeting of the c-Met–receptor.

Ian Wilson, CEO of EM Imaging, commented:

“Colorectal cancer is a major cause of death and this new agent has the potential to save thousands of lives through early detection. It gives providers the potential to effectively stratify patients, direct therapy choice and improve patient outcomes, while lowering the costs to the healthcare system. The team is extremely motivated to complete this product’s development and get it into the hands of clinicians in order to benefit patients. In addition EM Imaging will explore the utility of this new agent to visualise tumours during surgery, with studies planned to begin before the end of 2015.”

Sian Godwin, Head of Licencing at GE Healthcare, said:

“We’re pleased EM Imaging will develop and commercialise GE-137, as optical agents can be useful in clinical and research settings for a wide range of common diseases. We see broad partnership and licencing across our research and development portfolio as a way to increase access to new technologies in precision medicine, help develop better diagnostics for patients and reduce the cost of healthcare.”

Dr Neville Young, Programme Manager, Colorectal Therapies Healthcare Technologies Cooperative, said:

“The NIHR funded Colorectal Therapies HTC, based at the University of Leeds drives a national network of clinicians and academics who are funded to support the development innovative new technologies that have the potential to benefit patients affected by colorectal disease. We are excited to be working with EM Imaging to help demonstrate both the cost effectiveness and clinical efficacy of their new colorectal tumour tagging peptide. This technology offers the possibility to identify and remove more easily any cancerous polyps in a patient undergoing a colonoscopy.”

adminEM Imaging obtains global licence for optical agent that detects cancer early
read more

Edinburgh Molecular Imaging Ltd appoints new Chairman

Edinburgh, United Kingdom, 2nd September 2015 – The Board of Edinburgh Molecular Imaging Ltd (EM Imaging) is pleased to announce the appointment of John Jeans CBE CEng as non-executive Chairman with effect from 31st August 2015.

In an industrial career spanning 35 years John held senior international leadership positions in global companies including Smith & Nephew, Bristol Myers Squibb, Johnson & Johnson and Amersham plc (now GE Healthcare). John headed the commercial function of GE’s Life Science business and was the Chairman of its UK Healthcare Company. His domain expertise ranges from medical devices and pharmaceuticals to in-vivo and in-vitro diagnostics; encompassing research, product development, manufacturing and commercialisation.

John is Chairman of the Council of Cardiff University and Imanova. In addition he chairs the Board of UK Biocentre Ltd, is a non-executive Director of Renishaw plc and a Board member of the University and College Employers Association.

An advisor to public and third sector organisations, he was appointed by the Prime Minister in 2014 as the UK Government’s Life Science Champion for medical technology. John leads Innovate UK’s Stratified Medicine Advisory Board and the KTN’s Health Board, and has sat on advisory panels for the MRC, EPSRC, NIHR and the Wellcome Trust. He has served on several Government bodies including Co-Chairing a Ministerial Committee on Medical Technologies, is an inaugural member of the Science Advisory Council for Wales and a founder Trustee of the Francis Crick Institute. He is also Chair of the Strategic Advisory Panel for the Singapore Government’s Diagnostics Hub.

John was previously the Deputy Chief Executive of the Medical Research Council, a member of its Audit and Risk Committee and Chaired the Trustee Board of MRC Technology.

He was awarded a CBE for services to Life Sciences, Healthcare and Science in 2012.

Commenting on the changes to the Board, Ian Wilson, CEO of EMI, said:

“I am delighted to welcome John to the Board.  With his extensive experience in the healthcare and diagnostics sector John is an extremely valuable addition to the Company. His deep expertise and leadership skills will be central to supporting EM Imaging in bringing its novel optical imaging technology to the forefront of the global molecular imaging market.”

John Jeans said:

“The team at Edinburgh Molecular Imaging have made great progress in establishing a strong portfolio of optical imaging opportunities and it’s a privilege to be joining the Company as it enters this exciting period of further development”.

Further information:

 

Edinburgh Molecular Imaging

Ian Wilson, CEO:  info@emimaging.com

 

PLMR (Press Team)

Anokhi Madhavji: +44 (0)7415 701567

adminEdinburgh Molecular Imaging Ltd appoints new Chairman
read more

Highly specific, multi-branched fluorescent reporters for analysis of human neutrophil elastase

Human neutrophil elastase (HNE) is a serine protease implicated in the pathogenesis of acute and chronic inflammatory disease. Here a series of, internally quenched, single fluorophore fluorescent reporters were synthesised that allowed the rapid, highly specific and sensitive analysis of HNE activity over closely related proteases.

adminHighly specific, multi-branched fluorescent reporters for analysis of human neutrophil elastase
read more